Low-Dose Aspirin and Hepatic Fat Quantity in Patients With MASLD

To the Editor A recent clinical trial1 of the effect of low-dose aspirin on MASLD lasted 6 months and demonstrated that daily low-dose aspirin decreased hepatic fat content compared with placebo. However, I have some concerns about the applicability and long-term consequences of these results.